Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

The intelligence a $25K terminal charges for — the day it breaks, in your market, at a fraction of the price.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Executive ChangeItem 5.02 · 8-KMEDIUM RiskNeutral

Aquestive Therapeutics, Inc.

Filed: Mar 16, 2026CIK: 0001398733
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Aquestive Therapeutics announced the departure of Chief Legal Officer and Chief Compliance Officer Lori J. Braender effective April 2, 2026, though she will remain as Corporate Secretary and provide transition services through May 7, 2026. This leadership change signals ongoing restructuring efforts at the company.

Key Takeaways

Lori J. Braender is stepping down from Chief Legal Officer and Chief Compliance Officer roles effective April 2, 2026

She will remain with the company through May 7, 2026 to provide transition services while receiving her current base salary

2 more takeaways

Related Filings (3)

3 more filings from Aquestive Therapeutics, Inc. in the last 90 days

Filing Overview

Form Type8-K
Filing DateMar 16, 2026
Item5.02
CategoryExecutive Change
CIK0001398733
Accession #aqst-20260316
Risk LevelMEDIUM
SentimentNeutral
Signalinformational
Topics
executive departureleadership transitionrestructuring

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings